Hybrid Nanoparticles in Imaging and Therapy of Prostate*
混合纳米颗粒在前列腺成像和治疗中的应用*
基本信息
- 批准号:7916136
- 负责人:
- 金额:$ 15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAnimal ModelAnimalsArtsBindingBiologicalBombesinCancer CenterCarbohydratesCell surfaceCellsCharacteristicsComputersCore FacilityCoupledDetectionDevelopmentDiagnosisDimensionsDrug KineticsEducationEngineeringEnhancersExhibitsExperimental ModelsFamily suidaeGRP geneGenerationsGoalsGoldGum ArabicHumanHybridsImageImage EnhancementImaging TechniquesImplantIn SituIn VitroInterdisciplinary StudyInvestigationIsotopesLabelLeadLibrariesLiquid substanceMalignant NeoplasmsMalignant neoplasm of prostateMass Spectrum AnalysisMeasurementMembraneMetalsMissouriModalityModelingMusNanotechnologyNeutron Activation AnalysisPeptidesPhasePlasmaProductionPropertyProstateProstate Cancer therapyProstatic NeoplasmsProteinsProtocols documentationRadioactiveReactionResearchResearch InfrastructureResearch PersonnelResourcesRoentgen RaysSCID MiceScienceSepharoseSiteSpecificityStagingStarchStudy modelsSystemTechniquesTestingTheoretical modelTherapeuticTherapeutic AgentsTissuesTracerTransmission Electron MicroscopyTreatment EfficacyTumor Specific PeptideUltrasonographyUniversitiesVeterinary MedicineXenograft procedureabsorptionbasecancer cellcollegecombatconventional therapydesignimaging modalityin vivoinnovationmedical schoolsmodels and simulationmolecular imagingnanoparticlenanoparticulatenanoscalenanosciencephantom modelproduct developmentprogramsradiochemicalreceptorsimulationtomographytumortumor xenograft
项目摘要
DESCRIPTION (provided by applicant):
The University of Missouri (MU) Cancer Nanotechnology Platform (CNP) is the culmination of long-standing interdisciplinary partnerships in departments within the School of Medicine, the College of Arts and Science, the College of Veterinary Medicine, the Ellis Fischel Cancer Center, the Missouri University Research Reactor and the College of Engineering. Our CNP's overarching goal focuses on developing hybrid gold nanoparticle-based molecular imaging agents and targeted therapeutic agents that are effective in the diagnosis and treatment of prostate cancer. The specific objectives of our CNP include the following: (i) Synthesize and use a library of gold nanoparticles (AuNPs) for conjugation with prostate tumor-specific bombesin peptides. Investigate the photophysical properties, dispersity, and size-dimension measurements on these gold nanoparticles. (ii) Investigate biolocalization, pharmacokinetics and in vivo profiles of AuNPs stabilized with starch, agarose, and arabinagalactan protein (gum Arabic) in pigs. We will optimize analytical protocols, using techniques of neutron activation analysis (NAA), atomic absorption and radiochemical analysis using Au-198 nanoparticulate tracer, for the accurate estimation of AuNPs/gold metal in tissues and biological fluids, (iii) Develop new theoretical models, computations and simulations for the interaction of AuNPs with cells, (iv) Investigate the utility of AuNPs and bombesin-conjugated hybrid AuNPs as image enhancers in computed tomographic (CT) and ultrasound (US) imaging of prostate tumors in SCID mice implanted with human prostate cancer xenografts and with experimental modeling, simulations and studies on anthropomorphic phantom models of prostate cancer, (v) Optimize production of nanoparticulate a-emitting Au-198/199 and their utility for designing and developing tumor-specific Au-198/199-nanoparticlelabeled bombesin peptides for prostate tumor therapy. These studies will validate that multiple atoms of fiemitting Au-198 isotope, characteristic of nanoparticulate gold, will deliver significantly higher therapeutic payload to tumor sites than any conventional therapy. The MU Nanoparticles Production Core Facility will serve as a research and production resource for the unhindered supply of AuNPs to all investigators within the CNP program.
The CNP provides unique opportunities for professionals from diverse academic backgrounds to be involved in collaborative scientific interactions that further our interdisciplinary research, education and product development program. We will apply principles of nanoscience and nanotechnology to develop innovative molecular imaging and therapeutic approaches to combat prostate cancer.
描述(由申请人提供):
密苏里大学 (MU) 癌症纳米技术平台 (CNP) 是医学院、艺术与科学学院、兽医学院、埃利斯菲舍尔癌症中心、密苏里大学研究堆和工程学院。我们 CNP 的总体目标侧重于开发基于混合金纳米颗粒的分子成像剂和可有效诊断和治疗前列腺癌的靶向治疗剂。我们的 CNP 的具体目标包括以下内容:(i) 合成并使用金纳米颗粒 (AuNP) 库与前列腺肿瘤特异性铃蟾肽结合。研究这些金纳米粒子的光物理性质、分散性和尺寸测量。 (ii) 研究用淀粉、琼脂糖和阿拉伯半乳聚糖蛋白(阿拉伯树胶)稳定的 AuNP 在猪体内的生物定位、药代动力学和体内特征。我们将利用中子活化分析(NAA)、原子吸收和使用 Au-198 纳米颗粒示踪剂的放射化学分析技术来优化分析方案,以准确估计组织和生物体液中的 AuNPs/金金属,(iii)开发新的理论模型、AuNPs 与细胞相互作用的计算和模拟,(iv) 研究 AuNPs 和铃蟾肽共轭杂化 AuNPs 作为计算机断层扫描 (CT) 中图像增强剂的效用对植入人类前列腺癌异种移植物的 SCID 小鼠中的前列腺肿瘤进行超声(美国)成像,并对前列腺癌拟人化模型进行实验建模、模拟和研究,(v) 优化纳米粒子发射 Au-198/199 的生产和它们可用于设计和开发用于前列腺肿瘤治疗的肿瘤特异性 Au-198/199 纳米颗粒标记的铃蟾肽肽。这些研究将验证发射 Au-198 同位素的多个原子(纳米颗粒金的特征)将比任何传统疗法为肿瘤部位提供显着更高的治疗有效负载。 MU 纳米颗粒生产核心设施将作为研究和生产资源,为 CNP 项目内的所有研究人员不受阻碍地供应 AuNP。
CNP 为来自不同学术背景的专业人士提供了参与科学协作互动的独特机会,从而进一步推进我们的跨学科研究、教育和产品开发计划。我们将应用纳米科学和纳米技术的原理来开发创新的分子成像和治疗方法来对抗前列腺癌。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nanocompatible chemistry toward fabrication of target-specific gold nanoparticles.
纳米相容化学用于制造特定目标的金纳米颗粒。
- DOI:
- 发表时间:2006-09-06
- 期刊:
- 影响因子:15
- 作者:Kannan, Raghuraman;Rahing, Valerie;Cutler, Cathy;Pandrapragada, Ravi;Katti, Kavita K;Kattumuri, Vijaya;Robertson, J David;Casteel, Stan J;Jurisson, Silvia;Smith, Charles;Boote, Evan;Katti, Kattesh V
- 通讯作者:Katti, Kattesh V
Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine.
麦芽糖和阿拉伯树胶混合金纳米粒子静脉注射后在幼年猪体内的生物分布。
- DOI:
- 发表时间:2009-06
- 期刊:
- 影响因子:0
- 作者:Fent, Genevieve M;Casteel, Stan W;Kim, Dae Young;Kannan, Raghuraman;Katti, Kavita;Chanda, Nripen;Katti, Kattesh
- 通讯作者:Katti, Kattesh
Facile and General Method for Synthesis of Sugar Coated Gold Nanoparticles.
合成糖衣金纳米颗粒的简便通用方法。
- DOI:
- 发表时间:2009-01-01
- 期刊:
- 影响因子:0
- 作者:Katti, Kavita K;Kattumuri, Vijaya;Bhaskaran, Sharanya;Katti, Kattesh V;Kannan, Raghuraman
- 通讯作者:Kannan, Raghuraman
Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer.
层粘连蛋白受体特异性治疗性金纳米粒子 (198AuNP-EGCg) 显示出治疗前列腺癌的功效。
- DOI:
- 发表时间:2012-07-31
- 期刊:
- 影响因子:11.1
- 作者:Shukla, Ravi;Chanda, Nripen;Zambre, Ajit;Upendran, Anandhi;Katti, Kavita;Kulkarni, Rajesh R;Nune, Satish Kumar;Casteel, Stan W;Smith, Charles Jeffrey;Vimal, Jatin;Boote, Evan;Robertson, J David;Kan, Para;Engelbrecht, Hendrik;Watkinson, Lisa
- 通讯作者:Watkinson, Lisa
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kattesh V Katti其他文献
NSA_A_301942 69..89
NSA_A_301942 69..89
- DOI:
10.1524/ract.1999.84.1.31 - 发表时间:
2024-09-13 - 期刊:
- 影响因子:0
- 作者:
Theeranan Tangthong;Thananchai Piroonpan;Velaphi C Thipe;Menka Khoobch;ani;ani;Kavita Katti;Kattesh V Katti;Wanvimol Pasanphan - 通讯作者:
Wanvimol Pasanphan
Kattesh V Katti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kattesh V Katti', 18)}}的其他基金
Hybrid Nanoparticles in Imaging and Therapy of Prostate*
混合纳米颗粒在前列腺成像和治疗中的应用*
- 批准号:
7471541 - 财政年份:2005
- 资助金额:
$ 15万 - 项目类别:
Hybrid Nanoparticles in Imaging and Therapy of Prostate*
混合纳米颗粒在前列腺成像和治疗中的应用*
- 批准号:
7127272 - 财政年份:2005
- 资助金额:
$ 15万 - 项目类别:
Hybrid Nanoparticles in Imaging and Therapy of Prostate*
混合纳米颗粒在前列腺成像和治疗中的应用*
- 批准号:
7678993 - 财政年份:2005
- 资助金额:
$ 15万 - 项目类别:
Hybrid Nanoparticles in Imaging and Therapy of Prostate*
混合纳米颗粒在前列腺成像和治疗中的应用*
- 批准号:
7280361 - 财政年份:2005
- 资助金额:
$ 15万 - 项目类别:
Hybrid Nanoparticles in Imaging and Therapy of Prostate*
混合纳米颗粒在前列腺成像和治疗中的应用*
- 批准号:
7050771 - 财政年份:2005
- 资助金额:
$ 15万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
探索在急性呼吸窘迫综合征动物模型和患者长时间俯卧位通气过程中动态滴定呼气末正压的意义
- 批准号:82270081
- 批准年份:2022
- 资助金额:76 万元
- 项目类别:面上项目
脆性X综合征动物模型中异常视觉信息处理和视觉注意力的神经环路机制研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Partial and Controlled Depletion of SR Calcium by RyR Agonists Prevents Calcium-dependent Arrhythmias
RyR 激动剂部分且受控地消耗 SR 钙可预防钙依赖性心律失常
- 批准号:
10577630 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Protease-activated-receptor-2 antagonists for treatment of migraine pain
蛋白酶激活受体 2 拮抗剂治疗偏头痛
- 批准号:
10602826 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
N-acetylserotonin alleviates neurotoxicity in alcohol misuse following TBI
N-乙酰血清素可减轻 TBI 后酒精滥用造成的神经毒性
- 批准号:
10591834 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9
基于核酸的 Cas9 抗 CRISPR 抑制剂
- 批准号:
10864412 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别: